

Comprehensive multivariate risk modeling improves mortality risk prediction in pulmonary arterial hypertension

Supplementary Material

Innsbruck PAH registry

2021-11-24

Contents

Supplementary Methods	2
Data transformation, visualization, descriptive statistic	2
Hypothesis testing, multiple comparisons	2
Univariable Cox survival modeling	2
Development of custom risk signatures	2
Modeling of 5-year mortality	3
Data and code availability	3
Supplementary Tables	4
Supplementary Figures	8
References	16

Supplementary Methods

Data transformation, visualization, descriptive statistic

Data transformation, analysis and result visualization was accomplished by R version 4.0.5 with *tidyverse* environment(1,2). Figures were generated with *cowplot* package (3), Supplementary Material file was built with *rmarkdown* environment (packages *knitr*, *rmarkdown*, *kableExtra* and *bookdown*) (4).

For univariable survival modeling and construction of candidate risk signatures, a set of categorical 23 demographic, biochemical, right-heart catheter, laboratory, ultrasound and lung function parameters recorded at PH diagnosis was used. For the list of modeling variables and their stratification scheme, see: **Supplementary Table S1**.

Hypothesis testing, multiple comparisons

As the majority of the analyzed numeric variables were non-normally distributed as checked by Shapiro-Wilk test, differences in median values between analysis groups were investigated by Mann-Whitney and Kruskal-Wallis test, as appropriate. Differences in survival between groups were compared by Kaplan-Meier (KM) analysis, Mentel-Henszel and log-rank test (5), as appropriate. KM analysis and visualization of its results were done with tools provided by *survival* and *survminer* packages (6) and home-developed wrappers (<https://github.com/PiotrTymoszuk/KM-Toolbox>).

For each analysis and cohort, p values were corrected for multiple comparisons with Benjamini-Hochberg method (7).

Univariable Cox survival modeling

Association of candidate categorical variables (**Supplementary Table S1**) with overall survival time was assessed by series of univariable Cox proportional hazard models constructed for the Innsbruck and Linz/Vienna cohort using *survival* package (8) and home-developed wrappers (<https://github.com/PiotrTymoszuk/KM-Toolbox>). Significance of the hazard ratio estimates was determined by Wald Z test. P values were corrected for multiple comparisons with Benjamini-Hochberg method (7). For the full modeling results, see: **Supplementary Table S2**.

Development of custom risk signatures

Candidate risk signatures ($n = 10879$) were constructed as all possible combinations of 2 - 4 modeling variables (**Supplementary Table S1**). The development and selection of significant risk signatures involved a 3-step procedure (**Figure 3A**):

(1) Identification of the significant signatures in the PAH training Innsbruck cohort. Correlation of the candidate signatures with overall survival time was investigated in the training Innsbruck cohort by multivariable Cox proportional hazard modeling (*survival* package) (8). Out of 10879 tested signatures a total of 36 variable combinations displayed **(A)** significant hazard ratios for all model components (Wald Z test), **(B)** significant Harrell's concordance index (C-index, 2.5% confidence interval limit > 0.5 , *concordance()* function, *survival* package) (8,9) and **(C)** Benjamini-Hochberg-adjusted significance in likelihood ratio test versus the respective NULL model. For the complete multivariable Cox modeling results in the test cohort, see: **Supplementary Table S3**.

(2) Cross-validation (CV) in the training Innsbruck cohort. Ability of the signatures identified in Step 1 to reproducibly predict overall survival in the training Innsbruck cohort was assessed with 20-fold cross-validation essentially as described in (10). Briefly, for each training - test split of the Innsbruck cohort and the given variable combination, a multi-parameter Cox model was constructed in the training subset,

and its linear predictor values calculated in the test subset. Association of the linear predictor score in the test subset with survival was measured by C-index statistic. Out of the 36 signatures subjected to CV, 17 showed significant C-index values (2.5% confidence interval limit > 0.5).

(3) External validation in the PAH test Linz/Vienna cohort. The external validation procedure was based on procedure described in (11). For the signatures passing the CV selection in Step 2 linear predictor scores based on the training cohort Cox model estimates (see: **Supplementary Table S4** for the formulas) were calculated in the test Linz/Vienna cohort. Correlation of the linear predictor scores with overall survival in the testing cohort was assessed by Cox proportional hazard modeling and C-index statistic. All 17 CV-passing risk signatures demonstrated significant association with overall survival in the test cohort.

Values of mean squared errors and C-indexes in the training cohort (Step 1), cross-validation (Step 2) and test (Step 3) cohort are presented in **Figure 2** and **Supplementary Figure S1**.

Modeling of 5-year mortality

Linear predictor scores for the developed 17 risk signatures (**Supplementary Table S4**) were calculated in the test Innsbruck and training Linz/Vienna cohort. Association of the score values with 5-year mortality was assessed with logistic regression (generalized linear modeling, log-link function, binomial family) and receiver-operator characteristic (ROC). Optimal score cutoffs were determined by maximizing the Youden J statistic. Score cutoff, sensitivity, specificity and area-under the curve value determination were done with *optimal.cutpoints* package (12). ROC curve plotting was accomplished by *plotROC* package tools (13).

Data and code availability

The study data set is available at serious request to the corresponding author. The analysis R code was deposited on GitHub (<https://github.com/PiotrTymoszuk/PAH-biomarker>).

Supplementary Tables

Table S1: **Study variables.** Variable: variable name used in R code, Variable label: variable label used in plots and tables, Variable type: indicator whether the variable was used as a modeling response, independent variable (signature development) or comparator risk tool. Stratification: variable stratification scheme. The table is available online.

—
—
—

Table S2: **Results of univariable Cox proportional hazard modeling.** Variable: variable name and strata, HR: hazard ratio with 95% confidence interval, N: number of complete observations, pFDR: Benjamini-Hochberg-corrected p value for HR significance. The table is available online.

—
—
—

Table S3: **Results of multivariable Cox proportional hazard modeling for the candidate risk signatures in the training Innsbruck cohort.** Significant HRs: indicator if all model betas were significant, pLRT FDR: Benjamini-Hochberg-corrected p value for the likelihood ratio test, pWald FDR: Benjamini-Hochberg-corrected p value for the Wald test, C: concordance index with 95% confidence intervals, N: number of complete observations. The table is available online.

—
—
—

Table S4: **Formulas of linear predictor scores for the developed risk signatures.**

Signature	Score formula
Signature 3	$1.7 \times \text{Age: } >60 + -0.91 \times \text{CI: } 2 - 2.5 + -1.6 \times \text{CI: } \geq 2.5$
Signature 12	$1.7 \times \text{Age: } >60 + 1.8 \times \text{NtproBNP: } 300 - 1100 + 2.4 \times \text{NtproBNP: } \geq 1100$
Signature 14	$2.2 \times \text{Age: } >60 + 0.96 \times \text{Percard. Eff: yes}$
Signature 16	$2 \times \text{Age: } >60 + 1.3 \times \text{RAA: } >20.7$
Signature 17	$2.1 \times \text{Age: } >60 + 0.92 \times \text{RDW: } >14.5$
Signature 18	$2.2 \times \text{Age: } >60 + -0.77 \times \text{Sex: female}$
Signature 127	$0.72 \times \text{GFR: } <60 + 1.3 \times \text{RAA: } >20.7$
Signature 181	$0.78 \times \text{mPAP: } \geq 49 + 1.3 \times \text{RAA: } >20.7$
Signature 182	$1 \times \text{mPAP: } \geq 49 + 0.75 \times \text{RDW: } >14.5$
Signature 255	$2 \times \text{Age: } >60 + 0.92 \times \text{Anemia: yes} + -0.96 \times \text{CI: } 2 - 2.5 + -1.7 \times \text{CI: } \geq 2.5$
Signature 307	$1.8 \times \text{Age: } >60 + -0.87 \times \text{CI: } 2 - 2.5 + -1.3 \times \text{CI: } \geq 2.5 + 1.1 \times \text{RAA: } >20.7$
Signature 309	$1.8 \times \text{Age: } >60 + -1 \times \text{CI: } 2 - 2.5 + -1.6 \times \text{CI: } \geq 2.5 + -0.87 \times \text{Sex: female}$
Signature 412	$2.2 \times \text{Age: } >60 + 1 \times \text{mPAP: } \geq 49 + 1.1 \times \text{RAA: } >20.7$
Signature 450	$2.1 \times \text{Age: } >60 + 0.87 \times \text{Percard. Eff: yes} + 1.3 \times \text{RAA: } >20.7$
Signature 452	$2.3 \times \text{Age: } >60 + 0.87 \times \text{Percard. Eff: yes} + -0.71 \times \text{Sex: female}$
Signature 464	$2 \times \text{Age: } >60 + 1.2 \times \text{RAA: } >20.7 + 0.78 \times \text{RDW: } >14.5$
Signature 2525	$2.1 \times \text{Age: } >60 + -0.82 \times \text{CI: } 2 - 2.5 + -1.2 \times \text{CI: } \geq 2.5 + 0.91 \times \text{mPAP: } \geq 49 + -0.75 \times \text{Sex: female}$

Table S5: **Prediction of 5-year mortality by the developed signatures and established PH risk assessment tools investigated by receiver-operator characteristic.** J: Youden J statistic, AUC: area under the ROC curve with 95% confidence interval.

Cohort	Signature	Cutoff	Sensitivity	Specificity	J	AUC
IBK	Signature 3	0.83	0.86	0.60	0.46	0.8 [0.706 - 0.894]
	Signature 12	3.50	0.86	0.61	0.47	0.761 [0.656 - 0.866]
	Signature 14	2.20	0.90	0.42	0.33	0.698 [0.602 - 0.794]
	Signature 16	3.30	0.81	0.64	0.45	0.746 [0.657 - 0.835]
	Signature 17	3.00	0.52	0.81	0.34	0.743 [0.642 - 0.843]
	Signature 18	2.20	0.62	0.85	0.47	0.768 [0.654 - 0.883]
	Signature 127	1.30	0.90	0.48	0.38	0.738 [0.636 - 0.84]
	Signature 181	2.00	0.62	0.86	0.48	0.788 [0.681 - 0.895]
	Signature 182	1.00	0.62	0.81	0.43	0.77 [0.656 - 0.884]
	Signature 255	2.00	0.67	0.80	0.47	0.813 [0.721 - 0.905]
	Signature 307	1.10	0.90	0.57	0.48	0.821 [0.733 - 0.908]
	Signature 309	0.81	0.81	0.76	0.57	0.839 [0.742 - 0.936]
	Signature 412	4.30	0.62	0.92	0.54	0.824 [0.722 - 0.926]
	Signature 450	3.00	0.86	0.62	0.48	0.765 [0.675 - 0.854]
	Signature 452	2.30	0.71	0.81	0.53	0.785 [0.678 - 0.892]
	Signature 464	2.80	0.90	0.57	0.48	0.783 [0.689 - 0.878]
	Signature 2525	2.10	0.71	0.94	0.65	0.857 [0.754 - 0.96]
	mRASP	2.00	0.43	0.91	0.34	0.734 [0.623 - 0.846]
	COMPERA	2.00	1.00	0.28	0.28	0.708 [0.618 - 0.799]
	SPAHR	2.00	1.00	0.30	0.30	0.735 [0.65 - 0.821]
	FRENCH3p	2.00	0.95	0.31	0.26	0.635 [0.528 - 0.742]
	FRENCH4p	3.00	0.86	0.45	0.31	0.684 [0.575 - 0.792]
	Reveal Lite	2.00	0.90	0.41	0.32	0.679 [0.578 - 0.779]
	Reveal 2.0	3.00	0.81	0.52	0.33	0.678 [0.579 - 0.777]
	Signature 3	0.83	0.53	0.76	0.29	0.646 [0.484 - 0.807]
	Signature 12	4.00	0.53	0.79	0.32	0.677 [0.544 - 0.81]
	Signature 14	0.96	0.88	0.36	0.25	0.596 [0.486 - 0.706]
	Signature 16	1.30	0.88	0.31	0.19	0.619 [0.484 - 0.755]
	Signature 17	2.10	0.71	0.44	0.14	0.578 [0.436 - 0.719]
	Signature 18	2.20	0.41	0.83	0.25	0.653 [0.515 - 0.792]
	Signature 127	1.30	0.60	0.62	0.22	0.58 [0.435 - 0.725]
	Signature 181	0.78	0.76	0.51	0.28	0.635 [0.504 - 0.766]
	Signature 182	0.75	0.94	0.27	0.21	0.616 [0.496 - 0.737]
	Signature 255	1.10	0.59	0.72	0.31	0.645 [0.49 - 0.799]
	Signature 307	0.91	0.71	0.59	0.30	0.658 [0.511 - 0.804]

LZ/W	Signature 309	0.22	0.59	0.79	0.38	0.7 [0.549 - 0.851]
	Signature 412	3.20	0.59	0.70	0.29	0.631 [0.493 - 0.768]
	Signature 450	0.87	0.94	0.31	0.25	0.643 [0.516 - 0.769]
	Signature 452	0.00	1.00	0.28	0.28	0.669 [0.545 - 0.792]
	Signature 464	1.20	0.88	0.31	0.19	0.627 [0.492 - 0.761]
	Signature 2525	0.16	0.71	0.60	0.31	0.69 [0.549 - 0.83]
	mRASP	1.00	0.94	0.36	0.31	0.66 [0.56 - 0.76]
	COMPERA	2.00	0.88	0.38	0.26	0.642 [0.535 - 0.75]
	SPAHR	2.00	0.94	0.34	0.28	0.671 [0.579 - 0.763]
	FRENCH3p	3.00	0.65	0.65	0.29	0.674 [0.556 - 0.792]
	FRENCH4p	2.00	0.94	0.36	0.31	0.645 [0.532 - 0.759]

Supplementary Figures




Figure S1: Fit errors and overall survival prediction performance for the significant risk signatures.

Supplementary Figure S1. Fit errors and overall survival prediction performance for the significant risk signatures.

Correlation of the candidate 2 - 4 parameter risk signatures (all possible combinations of 23 variables, **Supplementary Table S1**) with overall survival (OS) in the Innsbruck training cohort (IBK) was investigated by Cox proportional hazard modeling and verified by 20-fold cross-validation (CV) (**Figure 3**). Model fit parameters (MSE: mean squared error) and prediction accuracy measures (concordance index: C-index) for the 17 developed significant signatures are presented.

(A, B) MSE in the training cohort, cross-validation and test cohort.

(C) C-index values with 95% confidence intervals in the training and cross-validation.




Figure S2: Sensitivity and specificity at predicting 5-year mortality.

Supplementary Figure S2. Sensitivity and specificity at predicting 5-year mortality for the developed risk signature and established PH risk assessment tools.

Association of the developed risk signatures (**Figure 3**) and established PH risk assessment tools with 5-year mortality was assessed with receiver-operator characteristic (ROC, **Supplementary Table S5**). Optimal risk score value was determined by the maximum of Youden J statistic. Sensitivity (**A**), specificity (**B**) and J values at the score cutoff in the training Innsbruck (IBK) and the test Linz/Vienna (LZ/W) cohorts are shown.




Figure S3: Characteristic of the developed risk signature 2525.

Supplementary Figure S3. Characteristic of the developed risk signature 2525.

The risk signatures predicting overall survival in PH were developed as presented in **Figures 3**.

(A) Values of hazard ratio estimates of the Cox proportional hazard models for the signature 2525 in the training Innsbruck (IBK) cohort are shown with 95% confidence intervals. Mean squared errors (MSE),

concordance indexes (C) with 95% confidence intervals and significance in likelihood ratio test (pLRT) are displayed in the plot captions.

(B) The signatures 2525 linear predictor scores (**Supplementary Table S4**) in the training Innsbruck (IBK) and test Linz/Vienna cohort (LZ/W) were stratified by quartiles (Q1: 1st, Q2: 2nd, Q3: 3rd and Q4: 4th) and the survival differences between the score strata were compared by Kaplan-Meier analysis and log-rank test. P values corrected for multiple comparisons with Benjamini-Hochberg method are shown in the plots.

(C) The ability of the signature 2525 linear predictor score (**Supplementary Table S4**) to predict five-year survival in the training Innsbruck (IBK) and test Linz/Vienna cohort (LZ/W) was assessed with receiver-operator characteristic (ROC, **Supplementary Table S5**). ROC curves for the signature 2525 and the established PH risk assessment tools are shown.




Figure S4: Scoring by the established PH risk assessment tools in gender and age strata.

Supplementary Figure S4. Scoring by the established PH risk assessment tools in gender and age strata.

The differences in scoring by the established PH risk assessment tools between the participants stratified by age class and sex (IBK: Innsbruck, LZ/W: Linz/Vienna cohort) were assessed by Kruskal-Wallis test. P values corrected for multiple comparisons with Benjamini-Hochberg method are shown in the plot captions. IBK ≤ 60 : male n = 11, female n = 25, IBK >60 : male n = 25, female n = 40, LZ/W ≤ 60 : male n = 12, female n = 35, LZ/W >60 : male n = 23, female n = 43.




Figure S5: Scoring by the REVEAL risk assessment tools in gender and age strata.

Supplementary Figure S5. Scoring by the REVEAL risk assessment tools in gender and age strata.

The differences in REVEAL 2.0 and REVEAL Lite scoring between the participants stratified by age class and sex in the Innsbruck (IBK) cohort were assessed by Kruskal-Wallis test. P values corrected for multiple comparisons with Benjamini-Hochberg method are shown in the plot captions. $IBK \leq 60$: male $n = 11$, female $n = 25$, $IBK > 60$: male $n = 25$, female $n = 40$.

References

1. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester J, et al. Welcome to the Tidyverse. *Journal of Open Source Software* (2019) 4:1686. doi:10.21105/joss.01686
2. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. 1st ed. New York: Springer-Verlag (2016). Available at: <https://ggplot2.tidyverse.org>
3. Wilke CO. *Fundamentals of Data Visualization: A Primer on Making Informative and Compelling Figures*. 1st ed. Sebastopol: O'Reilly Media (2019).
4. Xie Y. *Bookdown : authoring books and technical documents with R Markdown*. (2016).
5. Harrington DP, Fleming TR. A Class of Rank Test Procedures for Censored Survival Data. *Biometrika* (1982) 69:553. doi:10.2307/2335991
6. Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using 'ggplot2'. (2016) Available at: <https://cran.r-project.org/package=survminer>
7. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* (1995) 57:289–300. doi:10.1111/j.2517-6161.1995.tb02031.x
8. Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model*. 1st ed. New York: Springer Verlag (2000).
9. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Statistics in Medicine* (1996) 15:361–387. doi:10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
10. Simon RM, Subramanian J, Li MC, Menezes S. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. *Briefings in Bioinformatics* (2011) 12:203–214. doi:10.1093/bib/bbr001
11. Royston P, Altman DG. External validation of a Cox prognostic model: Principles and methods. *BMC Medical Research Methodology* (2013) 13:33. doi:10.1186/1471-2288-13-33
12. López-Ratón M, Rodríguez-Álvarez MX, Cadarso-Suárez C, Gude-Sampedro F. Optimalcutpoints: An R package for selecting optimal cutpoints in diagnostic tests. *Journal of Statistical Software* (2014) 61:1–36. doi:10.18637/jss.v061.i08
13. Sachs MC. Plotroc: A tool for plotting ROC curves. *Journal of Statistical Software* (2017) 79:1–19. doi:10.18637/jss.v079.c02